Docs rot faster than fruit. You refactor a function signature on Monday. The docs still show the old signature on Friday. By next month, half your documentation is lying to your users. Formatting is ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company's success ...

I recently saw a tweet showing how Google has acquired companies over the years and built products around them. Here is the link to the tweet if you want. Now, Google made another announcement: Google ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Systems like OpenAI’s GPT-5 are accelerating research in math, biology and chemistry. But there is a debate over whether it can do that work on its own. Credit...Agnes Jonas Supported by By Cade Metz ...

What makes a large language model like Claude, Gemini or ChatGPT capable of producing text that feels so human? It’s a question that fascinates many but remains shrouded in technical complexity. Below ...

Late Thursday, Mr. Musk’s chatbot, Grok, limited requests for A.I.-generated images on X to paid subscribers of the social media site amid an outcry from victims and regulators. By Kate Conger and ...

Wayne Unger does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...